NCT07889180Not yet recruiting
European Appleby Registry for Pancreatic Cancer
Prospective Pan-European Registry of Distal Pancreatectomy With Celiac Axis Resection
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The EURO-APPLEBY Registry is a prospective, multicenter European observational registry designed to characterize contemporary surgical practice and evaluate perioperative and long-term oncological outcomes in patients undergoing distal pancreatectomy with celiac axis resection (DP-CAR), also known as the modified Appleby procedure, for pancreatic ductal adenocarcinoma of the body and/or tail. Consecutive eligible patients undergoing elective DP-CAR with curative intent will be prospectively enrolled at participating European hepatopancreatobiliary centers over a 24-month recruitment period. Clinical, treatment-related, imaging, operative, pathological, postoperative, and follow-up data will be collected using standardized definitions and a harmonized electronic case report form. The primary objectives are to characterize postoperative morbidity and mortality, overall survival, and disease-free survival following DP-CAR. Secondary objectives include identifying factors associated with postoperative ischemic complications and oncological outcomes, evaluating the impact of neoadjuvant therapy and surgical approaches, and assessing variability in clinical practice and outcomes across participating centers. This observational registry will not modify routine clinical care. The findings are expected to support benchmarking, improve patient selection and perioperative management, and inform the development of evidence-based European recommendations for DP-CAR.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 15 Oct 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Dec 2028
- Lead sponsor
- Institut Investigacio Sanitaria Pere Virgili
- Diseases
- Pancreatic cancer
- NCT number
- NCT07889180
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Dec 2026 to the primary completion date, 1 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Another arterial resection in addition to CAR.
- Previous enrollment in the registry for the same surgical episode.
- \-
Other illness
- DP-CAR performed for indications other than pancreatic ductal adenocarcinoma (e.g., pancreatic neuroendocrine tumors, cystic neoplasms, metastatic lesions, benign disease or pancreatic traumatic injuries).
Other
- Emergency DP-CAR procedures.
Who the study is looking for
- Age ≥18 years.
- Pancreatic ductal adenocarcinoma of the pancreatic body and/or tail.
- Undergoing DP-CAR, irrespective of surgical approach (open, laparoscopic, robotic, or hybrid).
- Elective surgery performed with curative intent.
- Prospective enrollment in the registry with written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.